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Idiopathic thrombotic thrombocytopenic purpura–
hemolytic uremic syndrome (TTP-HUS) is a rare
disease responsive to treatment with plasma exchange
(PE) but with a high percentage of relapse or refrac-
tory patients. A severe deficiency of ADAMTS-13 (<5%
of normal activity), congenital or caused by an autoan-
tibody, may be specific for TTP and it has been pro-
posed that severe ADAMTS-13 deficiency now defines
TTP. B cells play a key role in both the development
and the perpetuation of autoimmunity, suggesting that
B-cell depletion could be a valuable treatment
approach for patients with idiopathic TTP-HUS. This
review of the literature focuses on the role of ritux-
imab, a chimeric monoclonal antibody directed against
CD20 antigen expressed by B lymphocytes, in
patients with relapsing or refractory TTP-HUS with or
without ADAMTS-13 deficiency, suggesting that ritux-
imab may produce clinical remission in a significant
proportion of patients. Rituximab therapy reduces
plasma requirement and avoids complications related
to salvage-immunosuppressive therapy. In conclusion,
rituximab provides an effective, well-tolerated, and
safe treatment option for patients with idiopathic TTP-
HUS, thus giving an alternative approach to the
current treatment based on PE.
T
hrombotic thrombocytopenic purpura (TTP)
is a rare disorder characterized by thrombocy-
topenia, microangiopathic hemolytic anemia,
neurologic and renal abnormalities, and fever;
however, since the above-reported diagnostic criteria do
not distinguish TTP from hemolytic uremic syndrome
(HUS), the comprehensive termTTP-HUS has been found
to be more suitable.1 In the absence of treatment the mor-
tality rate is approximately 90% but decreases to 10% or
less when immediate plasma exchange (PE) is initiated.2-8
Because of its dramatic effect on short- and long-term
outcome, it is now suggested to begin PE evenwhen all the
above criteria, in absence of alternative diagnosis, are not
fulfilled.2,3,5,8-10 The evident advantage of early initiation of
therapy along with the decreased diagnostic threshold has
resulted in a sevenfold increase of patients treated with PE
for TTP-HUS from 1981 to 1997.11
TTP symptoms are related to the presence of von
Willebrand factor (VWF)-rich platelet (PLT) thrombi in
arterioles and capillaries. VWF is a multimeric plasma
glycoprotein crucial for both PLT adhesion and
aggregation, especially at the high shear rates in the
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microvasculature. The size of VWF multimers is physi-
ologically regulated in vivo by a specific metalloprotease
called ADAMTS-13 (a disintegrin-like and metallopro-
tease with thrombospondin Type 1 repeats).12 A severe
deficiency of ADAMTS-13 (<5% of normal activity) may
be specific for TTP13 and it has been proposed that severe
ADAMTS-13 deficiency now defines TTP.14,15 ADAMTS-13
deficiency, caused by an autoantibody, provides a pos-
sible explanation for the effectiveness of PE (removal of
the autoantibody by apheresis; supply of ADAMTS-13 by
plasma replacement). Although its measurements have
been suggested to guide treatment decisions,14,16-19 at the
present it is not possible to establish the sensitivity of
ADAMTS-13 deficiency for identifying patients who may
respond or not to PE. Therapy with PE should be imple-
mented in all patients with TTP-HUS and continued
until resolution of signs and/or symptoms and normal-
ization of laboratory tests; this can require long-term
therapy.9-35 However, approximately 10% to 20% of TTP-
HUS patients shows lack of response;9 in those refractory
patients, different types of immunosuppressive treat-
ment have been proposed but unsuccesfully,14,30,31,33
including steroids or immunosuppressive or immune-
modulating agents.29,33 It has been reported that splenec-
tomy may induce a remission rate of 50% to 100% in
refractory or relapsing TTP patients,30 but some authors
reported a high rate of relapses mainly in those patients
with severe ADAMTS-13 deficiency.9,30,34,36 Such findings
were not confirmed by others who reported few relapses
in a large cohort of TTP patients underwent
splenectomy.31
Rituximab, a chimeric monoclonal antibody directed
against the CD20 antigen present on B lymphocytes, is
used in lymphoma patients and those with rheumatoid
arthritis.34 Its action relies on clearance of B lymphocytes
responsible for antibody production by complement-
dependent cytotoxicity, antibody-dependent cellular
cytotoxicity, or directly by inducing apoptosis.32,34 The
presence of ADAMTS-13 antibody-mediated deficiency
makes rituximab an ideal drug in TTP-HUS,12 especially in
those patients who are refractory to PE therapy. Although
high promisingly, case series only have reported efficacy
and safety of this anti-CD20 in TTP-HUS patients, thus
leaving unresolved questions regarding target population,
timing of initiation, duration of treatment, and usefulness
of concomitant PE.35-63 This review examines the evidence
base supporting the use of rituximab in the treatment of
refractory or relapsed TTP.
MATERIALS AND METHODS
Data search
Information for this review was compiled by searching
PubMed and Medline databases for articles published
from October 2002 up to October 2009. Only articles
published in English were considered. “Search” terms
included “thrombocytopenic,” “thrombotic,” “purpura,”
“ADAMTS 13,” “hemolytic,” “uremic,” and “syndrome”
in association with “refractory,” “relapsing,” “plasma
exchange,” “rituximab,” “monoclonal,” “anti-CD20,” and
“antibody.” Referenceswere chosen based on the evidence
of rituximab treatment in idiopathic refractory or relaps-
ing TTP-HUS and on the chronologic order of reporting it
in the literature.
Definition of outcomes
Remission was defined as sustained normal PLT count,
absence of clinical manifestations of TTP, and cessation of
PE. Refractory TTP was defined as failure to achieve either
a normal PLT count after 7 days of PE or deterioration in
clinical symptoms despite standard therapy during the
first episode of TTP.34 Relapsing TTP was defined as dete-
rioration of clinical and laboratory findings occurred after
sustained remission.9
REVIEW OF THE LITERATURE
A comprehensive list of article cited in this review is
reported in Table 1. The earliest report about acute refrac-
tory TTP treated successfully with rituximab involved two
cases.39 Fankouri and coworkers12 conducted a prospec-
tive multicenter open-label study to test the efficacy of
rituximab in the therapeutic or prophylactic treatment of
11 patients with TTP caused by the presence of inhibitory
antibodies against ADAMTS-13. Six patients with an
episode of acute refractory TTP and five patients with
relapsing TTP and persistence of anti-ADAMTS-13 were
treated. Target of treatment was to maintain ADAMTS-13
of more than 10%. Rituximab was given in courses of four
weekly doses of 375 mg/m2 and it led to clinical remission
in all cases, decreasing to not detectable level antibodies
to ADAMTS-13, and increasing ADAMTS-13 activity from
18% to 75%.
The largest case series involving a first episode of
acute refractory and relapsing idiopathic TTP was pub-
lished by Scully and coworkers.49 Twenty-five patients
received rituximab in conjunction with PE because of
progressive clinical disease or deterioration in laboratory
variables, despite intensive standard therapy. In relapsing
TTP, rituximab was started if antibody to ADAMTS-13
was demonstrated during previous episodes. On admis-
sion all patients received intravenous (IV) methylpred-
nisolone daily for 3 days. In total, 14 cases have been
reported that fulfilled the criteria of acute refractory TTP,
12 cases had ADAMTS-13 activity of less than 5%, one
case had 12% enzyme activity, and one case had no mea-
sured baseline ADAMTS-13 activity but had normal
ADAMTS-13 activity after 6 weeks of treatment elsewhere
with PE and prednisolone. Thirteen patients had
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evidence of an inhibitor to ADAMTS-13 and/or IgG
antibodies to ADAMTS-13 on admission. All patients
received a weekly IV rituximab infusion for 4 weeks
immediately after PE. The median ADAMTS-13 activity 3
months after four rituximab doses of 375 mg/m2 was
90% (range, 29%-109%) and there was also a significant
decrease in IgG antibody titer with no evidence of an
inhibitor in any patient (p < 0.0001). Rituximab deter-
mined rapid improvement of clinical features and
laboratory variables within a median of 11 days after
initiation of therapy; the drug was well tolerated and no
relapse of TTP occurred during a median follow up of 10
months (range, 1-33 months).
Ling and coworkers62 presented 13 patients with
refractory or relapsing TTP treated with rituximab. Twelve
of them (92%) achieved complete response; no subse-
quent relapses occurred with median follow-up of 24
months.
Subsequently Jasti and colleagues54 described 12
patients with TTP (11 with refractory and one with
relapsed disease) treated with rituximab. Of the 11
patients treated during the first episode ofTTP, ninemain-
tained remission for more than 59 months (range, 1-79
months). Two patients died during treatment. Regarding
patients treated because of relapsed TTP, he maintained
complete remission for 2 years. Then, due to a second
relapse, he was treated again with rituximab and even
in this case he maintained complete remission for 22
months. Rituximab was effective and maintain remission
for more than 21 months even when a third relapse
occurred.
Considering all the reports present in Table 1, 76 of
118 (64%) had refractory and 42 of 118 (36%) had relapsed
TTP. Among refractory patients 67 of 76 (88%) achieved
remission to rituximab treatment, with a median follow-
up of 10 to 24 months. Among relapsed patients, all
achieved complete remission after a median follow-up of
10 to 45.5 months. Since no specific regimen with anti-
CD20 has been proven to be effective in these, therapy is
mainly empirical. In the majority of studies evaluated, rit-
uximab was administrated along with PE or immunosup-
pressive drugs (Table 1). In the largest study in acute
refractory cases, the median numbers of PEs before ritux-
imab and after the first rituximab infusion were 13 and 9,
respectively.49 In the series by Fankouri and coworkers,12
patients prospectively included during a refractory acute
TTP had PE discontinued before treatment with ritux-
imab. In place of PE, plasma infusions (15-25 mL/kg/day)
were continued and progressively tapered after the induc-
tion of complete remission (CR). In some cases (21/118;
18%) complete remission was achieved after two or three
infusions of rituximab at a dose of 375 mg/m2 at weekly
intervals, while in others (17/118; 14%) this was achieved
after eight administrations. In one patient rituximab was
given at 100 mg/m2 in 12 weekly infusions.54
Serious side effects were not reported during or after
rituximab administration except in one case, 6 hours after
the drug infusion when the patient presented acute respi-
ratory failure and cardiogenic shock.44 In our experience
(Table 2) in relapsed or refractory TTP-HUS (with or
without ADAMTS-13 deficiency) rituximab was given at
the dose of 375 mg/m2 a shot a week for 1 month without
other drugs except steroids.
DISCUSSION
Idiopathic TTP-HUS is a life-threatening disease still
difficult to properly manage. Standard therapy is PE
performed daily, until resolution of symptoms and/or
normalization of laboratory values (recovery of PLT count,
increase of hemoglobin [Hb], decrease of lactate dehydro-
genase [LDH], and absence of peripheral schistocytosis).
The discovery that deficiency of ADAMTS-13 may be
related to the severity and prognosis of idiopathic TTP-
HUS has now been suggested to test such marker, at the
diagnosis or during remission, for identifying patients at
high risk for recurrent TTP-HUS.15-18 However, some
uncertainties still remain since ADAMTS-13 deficiency
does not allow the detection of all patients who may
be appropriately diagnosed as TTP-HUS.9,36,37 Moreover, it
is not possible to establish the sensitivity of ADAMTS-13
deficiency for identifying patients who may respond or
not to PE; therefore, at the present, there are no sufficient
data to safely manage TTP patients on ADAMTS-13
detection.
PE is an effective treatment for TTP because of the
clearance of antibodies against ADAMTS-13 protease
while it is not very effective in case of secondary TTP. Con-
sequently, it has been postulated that PEmay not be effec-
tive in patients without ADAMTS-13 deficiency but some
reports have been proven that it does.9,34,37 For these
reasons, PE remains the standard treatment for idiopathic
TTP-HUS independently from ADAMTS-13 detection.9
Despite the considerable improvement in survival
with daily PE in patients with idiopathicTTP-HUS, there is
a subset of patients with either delayed or absent response
to this treatment.9-35 In fact, approximately 10% to 20% of
TTP-HUS patients are refractory (even after several proce-
dures) or (early) relapsed early.52 However, in these cases,
additional therapy with immunosuppressive drugs (such
as steroids, cyclophosphamide, or cyclosporine) has not
been proven to be beneficial.14,30,31
Rituximab administration has been proven to be
effective in the treatment of acute refractory or relapsing
idiopathic TTP-HUS in patients with and without
ADAMTS-13–inhibitory antibodies38-55 even if, in this last
case, its mechanism of action is unclear. Kameda and col-
leagues34,37 postulated that B-cell depletion by anti-CD20
may reduce excessive cytokine production in patients
with secondary TTP and thus maintaining the level of von
CARAMAZZA ET AL.
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Willebrand multimers within the normal range. Similarly,
this mechanism may also explain the success of PE in
patients without ADAMTS-13 deficiency or in those with
secondary TTP-HUS. Moreover, rituximab had deter-
mined the disappearance of ADAMTS-13 inhibitors. Thus,
this drug may play a primary role in high-risk TTP
patients, defined as those who maintain low levels of
ADAMTS-13 and characterized by high probability of
relapsing.64 This antibody might also be used as mainte-
nance therapy in this group of patients even after a sus-
tained clinical and laboratory remission.60 Rituximab may
play also an important role as alternative treatment in
patients not eligible for PE because of serious related com-
plications such as nephropathy,12,43 pancreatitis,65 and
cerebral ischemia occurring during TTP.66
Our and other results are promising about the use of
rituximab inTTP patients but there is still a lack of reliable
data on timing schedule, dosage, long-term maintenance
and side effects. In Fig. 1 is proposed a flow chart for using
rituximab according to the evidence of published studies.
Although the optimal dose of rituximab in this setting
has not been fully established, standard treatment of
375 mg/m2 once weekly for 4 weeks looks effective and
safe.12,36,37,39-43,45,47-52,54,56 The effectiveness of a different
schedule of therapy, such as dose of 375 mg/m2 once or
twice or a reduction of the single administered dose,
needs further study.37,39,42,44,46,48,50,53
Obviously, it is necessary to balance risks and benefits
of different options. PE is expensive and often associated
with complications related to venous access including
infection, catheter thrombosis, hypoxemia, hypotension,
and transfusion reaction.27,28,56 Rituximab is usually well
tolerated and reactions are usually mild without causing
discontinuation of the drug.12,35,41,49,50 However, rarely
potentially life-threatening complications have been
reported, such as progressive multifocal leukoencephal-
opathy, viral infections, cardiovascular events, and renal
toxicity.38-40,49
New clinical trials are now ongoing and hopefully
they will furnish a response about the optimal manage-
ment of refractory or relapsed TTP patients including
the role of rituximab and the need for ADAMTS-13
detection.61,67
In the meantime, rituximab has been proven to be
effective in the treatment of relapses and may be used
in high-risk patients.12,36,42,49-51,54,57,60,62,63 Furthermore this
anti-CD20may be a therapeutic option in idiopathic TTP-
HUS patients, with or without ADAMTS13 deficiency, who
fail to respond after 7 to 14 days of standard treatment.
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